[{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Sheila Kumari Singh<\/i><\/u><\/presenter>. McMaster, Dundas, ON, Canada","CSlideId":"","ControlKey":"6bada346-5e2d-4b3b-9d3c-ac15d1cde469","ControlNumber":"8636","DisclosureBlock":"<b>&nbsp;S. K. Singh, <\/b> <br><b>Century Therapeutics Inc.<\/b> Stock, Stock Option, Grant\/Contract, Yes. <br><b>StemPharm Inc.<\/b> Stock Option, Other, Scientific Advisor, No. <br><b>Recombinetics Inc.<\/b> Other, Scientific Advisor, No.","End":"4\/10\/2022 7:45:00 AM","HasWebcast":null,"Highlights":[],"Id":"18083","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Sheila Singh, MD;PhD","PresenterKey":"2806cc4d-e88a-4db9-8bf8-7016c9493239","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Targeting clonal heterogeneity in treatment-refractory brain cancers with rationally designed immunotherapies: Advances and challenges","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  7:00AM","SessionId":"652","SessionOnDemand":"False","SessionTitle":"Targeting Clonal Heterogeneity in Treatment-refractory Brain Cancers with Rationally Designed Immunotherapies: Advances and Challenges","ShowChatLink":"false","Start":"4\/10\/2022 7:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Targeting clonal heterogeneity in treatment-refractory brain cancers with rationally designed immunotherapies: Advances and challenges","Topics":null,"cSlideId":""}]